Scienture Holdings, Inc. (SCNX) - Net Assets
Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) has net assets worth $64.10 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($87.73 Million) and total liabilities ($23.63 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Scienture Holdings, Inc. (SCNX) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $64.10 Million |
| % of Total Assets | 73.06% |
| Annual Growth Rate | 59.65% |
| 5-Year Change | 1759.87% |
| 10-Year Change | N/A |
| Growth Volatility | 3998.97 |
Scienture Holdings, Inc. - Net Assets Trend (2006–2025)
This chart illustrates how Scienture Holdings, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Scienture Holdings, Inc. stock valuation.
Annual Net Assets for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual net assets of Scienture Holdings, Inc. from 2006 to 2025. Also explore net asset momentum of Scienture Holdings, Inc. to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $70.12 Million | -11.32% |
| 2024-12-31 | $79.07 Million | +14479.46% |
| 2023-12-31 | $542.35K | +58.18% |
| 2022-12-31 | $342.87K | -90.91% |
| 2021-12-31 | $3.77 Million | -56.56% |
| 2020-12-31 | $8.68 Million | +109.63% |
| 2019-12-31 | $4.14 Million | +390.16% |
| 2018-12-31 | $844.67K | +370.79% |
| 2017-12-31 | $-311.93K | +72.83% |
| 2016-12-31 | $-1.15 Million | -529.96% |
| 2015-12-31 | $267.02K | -60.05% |
| 2014-12-31 | $668.44K | +410.78% |
| 2013-12-31 | $130.87K | +648.54% |
| 2012-12-31 | $17.48K | +847.46% |
| 2011-12-31 | $-2.34K | +100.00% |
| 2008-12-31 | $-48.01 Million | -259231.28% |
| 2007-12-31 | $-18.51K | -291.39% |
| 2006-12-31 | $9.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scienture Holdings, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8054181000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $406.00 | 0.00% |
| Other Components | $150.67 Million | 214.88% |
| Total Equity | $70.12 Million | 100.00% |
Scienture Holdings, Inc. Competitors by Market Cap
The table below lists competitors of Scienture Holdings, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GigaMedia Limited
F:GIFN
|
$13.93 Million |
|
SPARK VC S.A. ZY 10
F:8N2
|
$13.93 Million |
|
Neonode Inc
NASDAQ:NEON
|
$13.93 Million |
|
Miwon Chemical
KO:134380
|
$13.93 Million |
|
CSP Steel Center Public Company Limited
BK:CSP
|
$13.92 Million |
|
Toleranzia AB
ST:TOL
|
$13.91 Million |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
$13.90 Million |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
$13.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scienture Holdings, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 79,072,121 to 70,120,384, a change of -8,951,737 (-11.3%).
- Net loss of 41,512,264 reduced equity.
- New share issuances of 26,293,039 increased equity.
- Other factors increased equity by 6,267,488.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-41.51 Million | -59.2% |
| Share Issuances | $26.29 Million | +37.5% |
| Other Changes | $6.27 Million | +8.94% |
| Total Change | $- | -11.32% |
Book Value vs Market Value Analysis
This analysis compares Scienture Holdings, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.74x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.04x to 0.74x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $8.23 | $0.34 | x |
| 2007-12-31 | $-15.76 | $0.34 | x |
| 2008-12-31 | $-40859.57 | $0.34 | x |
| 2013-12-31 | $0.84 | $0.34 | x |
| 2014-12-31 | $2.02 | $0.34 | x |
| 2015-12-31 | $0.77 | $0.34 | x |
| 2016-12-31 | $-3.28 | $0.34 | x |
| 2017-12-31 | $-0.82 | $0.34 | x |
| 2018-12-31 | $2.18 | $0.34 | x |
| 2019-12-31 | $10.47 | $0.34 | x |
| 2020-12-31 | $16.90 | $0.34 | x |
| 2021-12-31 | $6.95 | $0.34 | x |
| 2022-12-31 | $1.35 | $0.34 | x |
| 2023-12-31 | $0.23 | $0.34 | x |
| 2024-12-31 | $21.64 | $0.34 | x |
| 2025-12-31 | $0.46 | $0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scienture Holdings, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -59.20%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9618.03%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.20x
- Recent ROE (-59.20%) is above the historical average (-402.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -90.20% | 0.00% | 0.00x | 1.36x | $-9.69K |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.33K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.70 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-183.72K |
| 2012 | -862.05% | -18.70% | 6.79x | 6.79x | $-152.46K |
| 2013 | -1598.05% | -218.78% | 2.37x | 3.09x | $-2.10 Million |
| 2014 | -301.01% | -134.47% | 1.22x | 1.83x | $-2.08 Million |
| 2015 | -418.39% | -38.36% | 1.44x | 7.59x | $-1.14 Million |
| 2016 | 0.00% | -111.21% | 7.36x | 0.00x | $-2.65 Million |
| 2017 | 0.00% | 9.86% | 4.75x | 0.00x | $320.18K |
| 2018 | 1.07% | 0.24% | 1.72x | 2.64x | $-75.43K |
| 2019 | -6.87% | -3.82% | 1.33x | 1.35x | $-698.45K |
| 2020 | -29.22% | -14.81% | 1.75x | 1.13x | $-3.40 Million |
| 2021 | -141.00% | -53.75% | 1.72x | 1.53x | $-5.69 Million |
| 2022 | -454.98% | -33.87% | 2.76x | 4.86x | $-3.55 Million |
| 2023 | -3290.03% | -1308.34% | 0.11x | 23.11x | $-17.90 Million |
| 2024 | 11.47% | 6634.66% | 0.00x | 1.33x | $1.16 Million |
| 2025 | -59.20% | -9618.03% | 0.01x | 1.20x | $-48.52 Million |
Industry Comparison
This section compares Scienture Holdings, Inc.'s net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,927,181,249
- Average return on equity (ROE) among peers: -83.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | $64.10 Million | -90.20% | 0.37x | $13.92 Million |
| Bimi International Medical Inc (BIMI) | $9.99 Million | -168.11% | 1.31x | $6.98K |
| High Tide Inc (HITI) | $-9.66 Million | 0.00% | 0.00x | $204.80 Million |
| Trxade Group Inc (MEDS) | $3.77 Million | -109.09% | 0.53x | $2.84 Million |
| PetMed Express Inc (PETS) | $757.29K | -373.27% | 4.95x | $34.62 Million |
| POMDOCTOR LIMITED American Depositary Shares (POM) | $-481.30 Million | 0.00% | 0.00x | $5.11 Million |
| Ridgetech, Inc. (RDGT) | $38.15 Million | -37.57% | 0.78x | $2.96 Million |
| SunLink Health Systems Inc (SSY) | $33.74 Million | 13.30% | 1.02x | $7.85 Million |
| Walgreens Boots Alliance Inc (WBA) | $23.82 Billion | 10.67% | 2.41x | $10.37 Billion |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more